Marie Egan, MD
Cards
Titles
Director, Cystic Fibrosis Center; Vice Chair for Research, Department of Pediatrics
Contact Info
Pediatric Pulmonology, Allergy, Immunology & Sleep Medicine
PO Box 208064
New Haven, CT 06520-8064
United States
Titles
Director, Cystic Fibrosis Center; Vice Chair for Research, Department of Pediatrics
Contact Info
Pediatric Pulmonology, Allergy, Immunology & Sleep Medicine
PO Box 208064
New Haven, CT 06520-8064
United States
Titles
Director, Cystic Fibrosis Center; Vice Chair for Research, Department of Pediatrics
Contact Info
Pediatric Pulmonology, Allergy, Immunology & Sleep Medicine
PO Box 208064
New Haven, CT 06520-8064
United States
About
Titles
Professor of Pediatrics (Respiratory) and of Cellular And Molecular Physiology
Director, Cystic Fibrosis Center; Vice Chair for Research, Department of PediatricsAppointments
Pediatric Pulmonology, Allergy, Immunology & Sleep Medicine
Interim Section ChiefDualPediatric Pulmonology, Allergy, Immunology & Sleep Medicine
ProfessorPrimaryCellular & Molecular Physiology
ProfessorSecondary
Other Departments & Organizations
- Cellular & Molecular Physiology
- CPIRT - Center for Pulmonary Injury, Inflammation, Repair and Therapeutics
- Graduate Program in Cellular and Molecular Physiology
- Molecular Medicine, Pharmacology, and Physiology
- Pediatric Asthma Program
- Pediatric Cystic Fibrosis Program
- Pediatric Faculty Development Group
- Pediatric Pulmonology, Allergy, Immunology & Sleep Medicine
- Pediatrics
- Program in Translational Biomedicine (PTB)
- Yale Combined Program in the Biological and Biomedical Sciences (BBS)
- Yale Medicine
- Yale Ventures
Education & Training
- Fellow
- The Eudowood Division of Pediatric Respiratory Sciences, Johns Hopkins Hospital (1992)
- Resident
- Johns Hopkins Hospital (1989)
- Intern
- The Johns Hopkins Hospital (1987)
- MD
- Mount Sinai School of Medicine (1986)
Research
Overview
Dr. Egan’s primary research interest is to understand the regulation of ion transport across the airway epithelia in health and disease. Transepithelial ion transport is responsible for maintaining the airway surface fluid, i.e. the periciliary fluid layer, which controls mucociliary clearance. Abnormalities in the ion channels and regulators of these channels can alter mucociliary clearance, leading to retained secretions, mucus plugging, infection, and lung destruction, as seen in cystic fibrosis. In CF, it is the abnormal function of the cystic fibrosis transmembrane conductance regulator (CFTR), a multifunctional protein encoded by the gene that is affected in cystic fibrosis (CF) that underlies the abnormal ion transport in affected organs.
The Egan lab uses a variety of electrophysiologic techniques to examine how CFTR expression affects transepithelial ion transport in airway epithelial cells. They have shown that CFTR can modulate other ion channels and, as its name implies, act as a conductance regulator. In addition, the laboratory is interested in examining how mutations in CFTR affect its ability to function. Lastly, the epithelium interacts with the airway microenvironment and primary immune cells to propagate disease. Dr. Egan has shown that CFTR functions in primary immune cells and this function is altered in CF contributing to disease.
The Egan lab has worked collaboratively to bring forth innovative platforms that could have great impact on CF patients such as gene editing.
Specialized Terms: Cystic fibrosis clinical studies; Cystic fibrosis basic science research (ion transport, Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) function) ion transport; Cystic fibrosis translational research studies (strategies to bypass or correct the basic defect) gene editing, immune response , pediatrics
Medical Subject Headings (MeSH)
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Emanuela Bruscia, PhD
Diane Krause, MD, PhD
John Geibel, DSc, MD, AGAF, MS, FRS
Thomas Murray, MD, PhD
Christina Barone
Clemente Britto-Leon, MD
Cystic Fibrosis
Cystic Fibrosis Transmembrane Conductance Regulator
Epithelial Cells
Lung
Inflammation
Macrophages
Publications
2024
Enhancing in vivo cell and tissue targeting by modulation of polymer nanoparticles and macrophage decoys
Piotrowski-Daspit A, Bracaglia L, Eaton D, Richfield O, Binns T, Albert C, Gould J, Mortlock R, Egan M, Pober J, Saltzman W. Enhancing in vivo cell and tissue targeting by modulation of polymer nanoparticles and macrophage decoys. Nature Communications 2024, 15: 4247. PMID: 38762483, PMCID: PMC11102454, DOI: 10.1038/s41467-024-48442-7.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsPoly(amine-co-esterPolymer nanoparticlesDelivery of nucleic acid therapeuticsCell-type tropismTissue tropismNucleic acid delivery vehiclesIn vivo deliveryIn vivo efficacyCirculation half-lifeNucleic acid therapeuticsVehicle characteristicsTunable propertiesBiodistribution assessmentPhysiological fatePolymer chemistrySurface propertiesPharmacokinetic modelTissue targetingNanoparticlesDistribution modifiersPolymeric nanoparticlesTropismPolymerDelivery vehiclesHalf-lifeUnderstanding Impact of CFTR Dysfunction on Airway Immune Cell Composition in Early Lung Disease Pathogenesis
Kockar Kizilirmak T, Yin H, Garrison A, Bruscia E, Egan M, Britto-Leon C. Understanding Impact of CFTR Dysfunction on Airway Immune Cell Composition in Early Lung Disease Pathogenesis. 2024, a6357-a6357. DOI: 10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a6357.Peer-Reviewed Original ResearchDe-labeling of Food Allergy in Electronic Medical Records for Cystic Fibrosis Patients to Avoid Unnecessary Food Restriction
Nguyen H, Bruscia E, Young J, Egan M, Leeds S. De-labeling of Food Allergy in Electronic Medical Records for Cystic Fibrosis Patients to Avoid Unnecessary Food Restriction. Journal Of Allergy And Clinical Immunology 2024, 153: ab114. DOI: 10.1016/j.jaci.2023.11.376.Peer-Reviewed Original Research
2023
Hemoptysis in the Time of COVID
Kockar Kizilirmak T, Brumer E, Panacherry S, Egan M. Hemoptysis in the Time of COVID. 2023, a1928-a1928. DOI: 10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a1928.Peer-Reviewed Original Research
2022
Recruited monocytes/macrophages drive pulmonary neutrophilic inflammation and irreversible lung tissue remodeling in cystic fibrosis
Öz H, Cheng E, Di Pietro C, Tebaldi T, Biancon G, Zeiss C, Zhang P, Huang P, Esquibies S, Britto C, Schupp J, Murray T, Halene S, Krause D, Egan M, Bruscia E. Recruited monocytes/macrophages drive pulmonary neutrophilic inflammation and irreversible lung tissue remodeling in cystic fibrosis. Cell Reports 2022, 41: 111797. PMID: 36516754, PMCID: PMC9833830, DOI: 10.1016/j.celrep.2022.111797.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsC motif chemokine receptor 2Monocytes/macrophagesLung tissue damageCystic fibrosisTissue damageCF lungPulmonary neutrophilic inflammationPro-inflammatory environmentChemokine receptor 2CF lung diseaseNumber of monocytesSpecific therapeutic agentsGrowth factor βCF transmembrane conductance regulatorLung hyperinflammationLung neutrophiliaNeutrophilic inflammationNeutrophil inflammationInflammation contributesLung damageNeutrophil recruitmentLung diseaseLung tissueReceptor 2Therapeutic targetIn vivo correction of cystic fibrosis mediated by PNA nanoparticles
Piotrowski-Daspit AS, Barone C, Lin CY, Deng Y, Wu D, Binns TC, Xu E, Ricciardi AS, Putman R, Garrison A, Nguyen R, Gupta A, Fan R, Glazer PM, Saltzman WM, Egan ME. In vivo correction of cystic fibrosis mediated by PNA nanoparticles. Science Advances 2022, 8: eabo0522. PMID: 36197984, PMCID: PMC9534507, DOI: 10.1126/sciadv.abo0522.Peer-Reviewed Original ResearchCitationsAltmetricConceptsCystic fibrosisF508del miceIntravenous deliveryPrimary nasal epithelial cellsMultiple organ dysfunctionNasal epithelial cellsUssing chamber assaysOrgan dysfunctionF508del cystic fibrosisVivo treatmentGI tissuesCF transmembrane conductance regulator (CFTR) geneChamber assaySystemic deliveryEpithelial cellsCF-causing mutationsFibrosisCFTR functionMiceTransmembrane conductance regulator geneTarget effectsAir-liquid interfaceDeliveryPartial gainViable optionRecruitment of monocytes primed to express heme oxygenase-1 ameliorates pathological lung inflammation in cystic fibrosis
Di Pietro C, Öz HH, Zhang PX, Cheng EC, Martis V, Bonfield TL, Kelley TJ, Jubin R, Abuchowski A, Krause DS, Egan ME, Murray TS, Bruscia EM. Recruitment of monocytes primed to express heme oxygenase-1 ameliorates pathological lung inflammation in cystic fibrosis. Experimental & Molecular Medicine 2022, 54: 639-652. PMID: 35581352, PMCID: PMC9166813, DOI: 10.1038/s12276-022-00770-8.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsHeme oxygenase-1Cystic fibrosisOxygenase-1Myeloid differentiation factor 88Neutrophilic pulmonary inflammationChronic airway infectionDifferentiation factor 88HO-1 levelsDisease mouse modelPseudomonas aeruginosaRecruitment of monocytesResolution of inflammationMonocytes/macrophagesTreatment of CFConditional knockout miceMechanism of actionLung neutrophiliaNeutrophilic inflammationLung inflammationAirway infectionPulmonary diseasePulmonary inflammationFactor 88Lung damageProinflammatory cytokinesSurface conjugation of antibodies improves nanoparticle uptake in bronchial epithelial cells
Luks VL, Mandl H, DiRito J, Barone C, Freedman-Weiss MR, Ricciardi AS, Tietjen GG, Egan ME, Saltzman WM, Stitelman DH. Surface conjugation of antibodies improves nanoparticle uptake in bronchial epithelial cells. PLOS ONE 2022, 17: e0266218. PMID: 35385514, PMCID: PMC8986008, DOI: 10.1371/journal.pone.0266218.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsTarget-specific antibodiesNanoparticle uptakeSurface conjugationNanoparticle surface modificationSurface of nanoparticlesCellular uptakeSite-specific geneSpecific cellular bindingNanoparticlesIntracellular deliveryEditing reagentsBronchial epithelial cellsSurface modificationCellular targetingCystic fibrosisTherapeutic agentsEpithelial cellsParticle uptakeFeasible strategyGenetic diseasesFirst demonstrationHuman bronchial epithelial cellsKinetics of antibodiesCellular bindingAppropriate antibodies
2021
558: Carbon monoxide–based therapy primes macrophages to express HO-1 and to resolve lung hyper-inflammation in cystic fibrosis
Pietro C, Öz H, Zhang P, Cheng E, Martis V, Bonfield T, Kelley T, Jubin R, Abuchowski A, Krause D, Egan M, Murray T, Bruscia E. 558: Carbon monoxide–based therapy primes macrophages to express HO-1 and to resolve lung hyper-inflammation in cystic fibrosis. Journal Of Cystic Fibrosis 2021, 20: s263-s264. DOI: 10.1016/s1569-1993(21)01981-0.Peer-Reviewed Original Research582: In vivo nanoparticle-mediated therapeutic nucleic acid delivery for CF treatment
Piotrowski-Daspit A, Bracaglia L, Barone C, Nguyen R, Glazer P, Egan M, Saltzman W. 582: In vivo nanoparticle-mediated therapeutic nucleic acid delivery for CF treatment. Journal Of Cystic Fibrosis 2021, 20: s277. DOI: 10.1016/s1569-1993(21)02005-1.Peer-Reviewed Original ResearchCitations
Clinical Trials
Current Trials
VX-121 Combination Therapy in Subjects With Cystic Fibrosis VX20-121-103
HIC ID2000030926RolePrincipal InvestigatorPrimary Completion Date07/31/2023Recruiting ParticipantsGenderBothAge12+ yearsScreening In Anticipation of Future Research
HIC ID2000021443RoleSub InvestigatorPrimary Completion Date12/31/2022Recruiting ParticipantsGenderBothAge2 years - 17 years
Academic Achievements and Community Involvement
activity Member
Public ServiceDetailsDescriptionCystic Fibrosis Foundation CT Chapter Board Memberactivity Member
Professional OrganizationsDetailsDescriptionATS Pediatric Assembly Planning Committeeactivity Member
Professional OrganizationsDetailsDescriptionAmerican Board of Pediatrics Pulmonary Suboardactivity Member
Peer Review Groups and Grant Study SectionsDetailsDescriptionCystic Fibrosis Foundation Research Review Committeeactivity Member
Public ServiceDetails2008 - PresentDescriptionDrug Monitoring Safety Board CF Foundation
Clinical Care
Overview
Clinical Specialties
Fact Sheets
Cystic Fibrosis in Children
Learn More on Yale MedicinePediatric Respiratory Failure
Learn More on Yale MedicinePneumonia
Learn More on Yale MedicineAsthma
Learn More on Yale Medicine
Yale Medicine News
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileLinks & Media
News
Get In Touch
Contacts
Pediatric Pulmonology, Allergy, Immunology & Sleep Medicine
PO Box 208064
New Haven, CT 06520-8064
United States
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.